Targeting the multidrug ABCG2 transporter with flavonoidic inhibitors: In Vitro optimization and in vivo validation

Current Medicinal Chemistry

Volumn 18, Issue 22, 2011, Pages 3387-3401

  Boumendjel, A ^b   MacAlou, S ^a   Valdameri, G ^a,c   Pozza, A ^a   Gauthier, C ^a   Arnaud, O ^a   Nicolle, E ^b   Magnard, S ^a   Falson, P ^a   Terreux, R ^a   Carrupt, P A ^d   Payen, L ^a   Di Pietro, A ^a  

^a UNIVERSITÉ LYON 1   (France)

^b Université Joseph Fourier   (France)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

ABCG2; Breast cancer resistance protein; Drug design; Flavonoids; Inhibitors; Molecular models; Multidrug resistance; Quantitative Structure Activity Relationships

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; 3',4',7 TRIMETHOXYFLAVONE; 5,7 DIMETHOXYFLAVONE; 6 PRENYLCHRYSIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 8 METHYLFLAVONE; 8 PRENYLCHRYSIN; ANTINEOPLASTIC AGENT; BIOCHANIN A; BOERAVINONE G; BREAST CANCER RESISTANCE PROTEIN; BREAST CANCER RESISTANCE PROTEIN INHIBITOR; CANERTINIB; CANNABIDIOL; CANNABINOL; CHRYSIN; CURCUMIN; DRONABINOL; ELACRIDAR; FUMITREMORGIN C; IMATINIB; ISOKAEMPFERIDE; MULTIDRUG RESISTANCE PROTEIN 1; NOVOBIOCIN; PIPERAZINEDIONE; TARIQUIDAR; TECTOCHRYSIN; TOPOTECAN; TRYPROSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

COMPUTER MODEL; CONFERENCE PAPER; DRUG DESIGN; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VALIDATION STUDY;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; DRUG RESISTANCE, MULTIPLE; FEMALE; FLAVONOIDS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; POLYPHENOLS;

EID: 79961092422     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796504736     Document Type: Conference Paper

References (153)

1. Allikmets, R.; Schriml, L.M.; Hutchinson, A.; Romano-Spica, V.; Dean, M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res., 1998, 58(23), 5337-5339. (Pubitemid 28551112)
2. Doyle, L.A.; Yang, W.; Abruzzo, L.V.; Krogmann, T.; Gao, Y.; Rishi, A.K.; Ross, D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U.S.A., 1998, 95(26), 15665-15670. (Pubitemid 29018757)
3. Miyake, K.; Mickley, L.; Litman, T.; Zhan, Z.; Robey, R.; Cristensen, B.; Brangi, M.; Greenberger, L.; Dean, M.; Fojo, T.; Bates, S.E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res., 1999, 59(1), 8-13. (Pubitemid 29062946)
4. Hung, L.W.; Wang, I.X.; Nikaido, K.; Liu, P.Q.; Ames, G.F.; Kim, S.H. Crystal structure of the ATP-binding subunit of an ABC transporter. Nature,1998, 396(6712), 703-707. (Pubitemid 29003952)
5. Ambudkar, S.V.; Kim, I.W.; Xia, D.; Sauna, Z.E. The A-loop, a novel conserved aromatic acid subdomain upstream the Walker A motif in ABC transporters, is critical for ATP binding. FEBS Lett., 2006, 580(4), 7605-7616.
6. Smith, P.C.; Karpowich, N.; Millen, L.; Moody, J.E.; Rosen, J.; Thomas, P.J.; Hunt, J.F. ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide danwich dimer. Mol. Cell, 2002, 10(1), 139-149. (Pubitemid 34876568)
7. Hanekop, N.; Zaitseva, J.; Jenewein, S.; Holland, I.B.; Schmitt, L. Molecular insights into the mechanism of ATP hydrolysis by the NBD of the ABCtransporter HlyB. FEBS Lett., 2006, 580(4), 3432-3443.
8. Dawson, R.J.; Locher, K.P. Structure of a bacterial multidrug ABC transporter. Nature, 2006, 443(7108), 180-185. (Pubitemid 44387602)
9. Ward, A.; Reyes, C.L.; Yu, J.; Roth, C.B.; Chang, G. Flexibility in the ABC transporter MsbA: alternating access with a twist. Proc. Natl. Acad. Sci. USA, 2007, 104(48), 19005-19010.
10. Polgar, O.; Robey, R.W.; Morisaki, K.; Dean, M.; Michejda, C.; Sauna, Z.E.; Ambudkar, S.V.; Tarasova, N.; Bates, S.E. Mutational analysis of ABCG2: role of the GXXXG motif. Biochemistry, 2004, 43(29), 9448-9456. (Pubitemid 38955477)
11. Bhatia, A.; Schäfer, H.J.; Hrycyna, C.A. Oligomerization of the human ABC transporter ABCG2: evaluation of the native protein and chimeric dimers. Biochemistry, 2005, 44(32), 10893-10904. (Pubitemid 41153650)
12. Xu, J.; Liu, Y.; Yang, Y.; Bates, S.E.; Zhang, J.T. Characterization of oligomeric human half-transporter ATP-binding cassette G2. J. Biol. Chem., 2004, 279(19), 19781-19789. (Pubitemid 38623417)
13. McDewitt, C.A.; Collins, R.F.; Conway, M.; Modok, S., Storm, J.; Kerr, I.D.; Ford, R.C.; Callaghan, R. Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. Structure, 2006, 14(11), 1623-1632. (Pubitemid 46107268)
14. Dezi, M.; Fribourg, P.F.; Di Cicco, A.; Arnaud, O., Marco, S.; Falson, P.; Di Pietro, A.; Levy, D. The multidrug resistance half-transporter ABCG2 is purified as a tetramer upon selective extraction from membranes. BBA Biomembranes, 2010, 1798, 2094-2101.
15. Henriksen, U.; Fog, J.U.; Litman, T.; Gether, U. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. J. Biol. Chem., 2005, 280(44), 36926-36934. (Pubitemid 41587775)
16. Kage, K.; Fujita, T.; Sugimoto, Y. Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2. Cancer Sci., 2005, 96(12), 866-872. (Pubitemid 43056124)
17. Davidson, A.L.; Chen, J. ATP-binding cassette transporters in bacteria. Annu. Rev. Biochem., 2004, 73, 241-268. (Pubitemid 39050369)
18. Li, Y.F.; Polgar, O.; Esser, L.; Bates, S.E.; Xia, D. Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling study. J. Mol. Graph. Model., 2007, 25(6), 837-851. (Pubitemid 46216119)
19. Hazai, E.; Bikadi, Z. Homology modeling of breast cancer resistance protein (ABCG2). J. Struct. Biol., 2008, 162(1), 63-74.
20. Dawson, R.J.; Hollenstein, K.; Locher, K.P. Uptake or extrusion: crystal structures of full transporters suggest a common mechanism. Mol. Microbiol., 2007, 65(2), 250-257. (Pubitemid 47052721)
21. Xu, J.; Peng, H.; Chen, Q.; Liu, Y.; Dong, Z.; Zhang, J.T. Oligomerization domain of the multidrug resitance-associated transporter ABCG2 and its dominant inhibitory activity. Cancer Res., 2007, 67(9), 4373-4381. (Pubitemid 46815086)
22. Ozvegy-Laczka, C.; Laczko, R.; Hegedus, C.; Litman, T.; Varady, G.; Goda, K.; Hegedus, T.; Dokholyan, N.V.; Sorrentino, B.P., Varadi, A.; Sarkadi, B. Interaction with the 5D3 monoclonal antibody is regulaterd by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter. J. Biol. Chem., 2008, 283(38), 26059-26070.
23. Doyle, L.A.; Ross, D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene, 2003, 22(47), 7340-7358. (Pubitemid 37487163)
24. Wang, H.; Zhou, L.; Gupta, A.; Vethanayagam, R.R.; Zhang, Y.; Unadkat, J.D.; Mao, Q. Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells. Am. J. Physiol. Endocrinol. Metab., 2006, 290(5), E798-807.
25. Imai, Y.; Ishikawa, E.; Asada, S.; Sugimoto, Y. Estrogen-mediated posttranscriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res., 2005, 65(2), 596-604.
26. Honorat, M.; Mesnier, A.; Di Pietro, A.; Lin, V.; Cohen, P.; Dumontet, C.; Payen, L. Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells. Biochem. Biophys. Res. Commun., 2008, 375(3), 308-314.
27. Imai, Y.; Asada, S., Tsukahara, S.; Ishikawa, E.; Tsuruo, T.; Sugimoto, Y. Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol. Pharmacol., 2003, 64(3), 610-618. (Pubitemid 37048564)
28. Loscher, W.; Potska, H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci., 2005, 6, 591-602. (Pubitemid 41059334)
29. Breedveld, P.; Beijnen, J.H.; Schellens, J.H.M. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharm. Sci., 2006, 27(1), 17-24. (Pubitemid 43063120)
30. Bihorel, S.; Camenish, G.; Lemaire, M.; Scherrmann, J.M. Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm. Res., 2007, 24(9), 1720-1728. (Pubitemid 47206611)
31. Zhou, S.; Schuetz, J.D.; Bunting, K.D.; Colapietro, A.M.; Sampath, J.; Morris, J.J.; Lagutina, I.; Grosveld, G.C.; Osawa, M.; Nakauchi, H.; Sorrentino, B.P. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med., 2001, 7(9), 1028-1034. (Pubitemid 32937383)
32. Desuzinges-Mandon, E.; Arnaud, O.; Martinez, L., Huché, F.; Di Pietro, A.; Falson, P. ABCG2 transports and transfers heme to albumin through its large extracellular loop. J. Biol. Chem., 2010, 285, 33123-33133.
33. Krishnamurthy, P., Ross, D.D.; Nakanishi, T.; Bailey-Dell, K.; Zhou, S.; Mercer, K.E.; Sarkadi, B.; Sorrentino, B.P.; Schuetz, J.D. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem., 2004, 279(23), 24218-24225. (Pubitemid 38725283)
34. Dean, M.; Fojo, T.; Bates, S.E. Tumour stem cells and drug resistance. Nat. Rev. Cancer, 2005, 5(4), 275-284. (Pubitemid 40488633)
35. Robey, R.W.; Polgar, O.; Deeken, J.; To, K.W.; Bates, S.E. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev., 2007, 26(1),39-57. (Pubitemid 46452182)
36. Diestra, J.E.; Scheffer, G.L.; Catala, I.; Maliepaard, M.; Schellens, J.H.; Scheper, R.J.; Germa-Lluch, J.R.; Isquierdo, M.A. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffinembedded material. J. Pathol., 2002, 198(2), 213-219. (Pubitemid 35243879)
37. Galimberti, S.; Guerrini, F.; Palumbo, G.A.; Consoli, U.; Fazzi, R.; Morabito, F.; Santini, V.; Petrini, M. Evaluation of BCRP and MDR-1 coexpression by quantitative molecular assessment in AML patients. Leuk. Res., 2004, 28(4), 367-372. (Pubitemid 38199944)
38. Benderra, Z.; Faussat, A.M.; Sayada, L.; Perrot, J.Y.; Chaoui, D.; Marie, J.P.; Legrand, O. Breast cancer resistance protein and P-glycoprotein in 149 adult acute leukemias. Clin. Cancer Res., 2004, 10(23), 7896-7902. (Pubitemid 39587528)
39. Steinbach, D.; Legrand, O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra ? Leukemia, 2007, 21(6), 1172-1176. (Pubitemid 46831804)
40. Polgar, O.; Robey, R.W.; Bates, S.E. ABCG2: structure, function and role in drug resistance. Expert Opin. Drug Metab. Toxicol., 2008, 4(1), 1-15.
41. Allen, J.D.; Brinkhuis, R.F.; Wijnholds, J.; Schinkel, A.H. The mouse Bcrp1/Mxr/abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res., 1999, 59(17), 4237-4241. (Pubitemid 29418735)
42. Schellens, J.H.; Maliepaard, M.; Scheper, R.J.; Scheffer, G.L.; Jonker, J.W.; Smit, J.W.; Beijnen, J.H.; Schinkel, A.H. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical applications. Ann. N. Y. Acad. Sci., 2000, 922, 188-194. (Pubitemid 32050253)
43. Kawabata, S.; Oka, M.; Shiozawa, K.; Tsukamoto, K.; Nakatomi, K.; Soda, H.; Fukuda, M.; Ikegami, Y.; Sugahara, K.; Yamada, Y.; Kamihira, S.; Doyle, L.A.; Ross, D.D.; Kohno, S. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem. Biophys. Res. Commun., 2001, 280(5), 1216-1223. (Pubitemid 32917772)
44. Volk, E.L.; Farley, K.M.; Wu, Y.; Li, F.; Robey, R.W.; Schneider, E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res., 2002, 62(17), 5035-5040. (Pubitemid 34984431)
45. Allen, J.D.; van Dort, S.C.; Buitelaar, M.; van Tellingen, O.; Schinkel, A.H. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res., 2003, 63(6), 1339-1344. (Pubitemid 36348714)
46. Burger, H.; van Tol, H.; Boersma, A.W.; Brok, M.; Wiemer, E.A.; Stoter, G.; Nooter, K. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood, 2004, 104(9), 2940-2942. (Pubitemid 39434984)
47. Elkind, N.B.; Szentpetery, Z.; Apati, A.; Ozvegy-Laczka, C.; Varady, G.; Ujhelly, O.; Szabo, K.; Homolya, L.; Varadi, A.; Buday, L.; Keri, G.; Nemet, K.; Sarkadi, B. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res., 2005, 65(5), 1770-1777. (Pubitemid 40478603)
48. Brendel, C.; Scharenberg, C.; Dohse, M.; Robey, R.W.; Bates, S.E.; Shukla, S.; Ambudkar, S.V.; Wang, Y.; Wennemuth, G.; Burchert, A.; Boudriot, U.; Neubauer, A. Imatinib mesylate and nilotinib (AMN107) exhibit highaffinity interaction with ABCG2 on primitive hematopoietic cells. Leukemia, 2007, 21(6), 1267-1275. (Pubitemid 46831816)
49. Robey, R.W.; Medina-Perez, W.Y.; Nishiyama, K.; Lahusen, T.; Miyake, K.; Litman, T.; Senderowicz, A.M.; Ross, D.D.; Bates, S.E. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res., 2001, 7(1), 145-152. (Pubitemid 32110217)
50. Komatani, H.; Kotani, H.; Hara, Y.; Nakagawa, R.; Matsumoto, M.; Arakawa, H.; Nishimura, S. Identification of breast cancer resistant protein/ mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res., 2001, 61(7), 2827-2832. (Pubitemid 32691919)
51. Breedveld, P.; Pluim, D.; Cipriani, G.; Dalhaus, F.; van Eijndhoven, M.A.J.; de Wolf, C.J.F.; Kuil, A.; Beijnen, J.H.; Scheffer, G.L.; Jansen, G.; Borst, P.; Schellens, J.H.M. The effect of low pH on Breast Cancer Resistance Protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol. Pharmacol., 2007, 71, 240-249. (Pubitemid 46020994)
52. An, G.; Gallegos, M.; Morris, M. E. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. Drug Metab. Dispos., 2010, in press.
53. Wang, X.; Nitanda, T.; Shi, M.; Okamoto, M.; Furukawa, T.; Sugimoto, Y.; Akiyama, S.; Baba, M. Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. Biochem. Pharmacol., 2004, 68(7), 1363-1370. (Pubitemid 39179395)
54. Wang, X.; Furukawa, T.; Nitanda, T., Okamoto, M.; Sugimoto, Y.; Akiyama, S.; Baba, M. Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol., 2003, 63(1), 65-72. (Pubitemid 36043809)
55. Pan, G.; Giri, N.; Elmquist, W.F. Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab. Dispos., 2007, 35(7), 1165-1173. (Pubitemid 46956438)
56. Robey, R.W.; Steadman, K.; Polgar, O.; Morisaki, K.; Blayney, M.; Mistry, P.; Bates, S.E. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res., 2004, 64(4), 1242-1246. (Pubitemid 38235589)
57. van Herwaarden, A.E.; Wagenaar, E.; Karnekamp, B.; Merino, G.; Jonker, J.W.; Schinkel, A.H. Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis, 2006, 27(1), 123-130. (Pubitemid 43025252)
58. Merino, G.; Alvarez, A.I.; Pulido, M.M.; Molina, A.J.; Schinkel, A.H.; Prieto, J.G. Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metab. Dispos., 2006, 34(4), 690-695.
59. Zhang, Y.; Gupta, A.; Wang, H.; Zhou, L.; Vethanayagam, R.R.; Unadkat, J.D.; Mao, Q. BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res., 2005, 22(12), 2023-2034. (Pubitemid 41821581)
60. Litman, T.; Brangi, M.; Hudson, E.; Fetsch, P.; Abati, A.; Ross, D.D.; Miyake, K.; Resau, J.H.; Bates, S.E. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci., 2000, 113(11), 2011-2021. (Pubitemid 30386505)
61. Honjo, Y., Hrycyna, C.A.; Yan, Q.W., Medina-Perez, W.Y.; Robey, R.W.; van de Laar, A.; Litman, T.; Dean, M.; Bates, S.E. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCPoverexpressing cells. Cancer Res., 2001, 61(18), 6635-6639. (Pubitemid 32896477)
62. Robey, R.W.; Honjo, Y.; Morisaki, K.; Nadjem, T.A.; Runge, S.; Risbood, M.; Poruchynski, M.S.; Bates, S.E. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer, 2003, 89(10), 1971-1978. (Pubitemid 37533279)
63. Pozza, A.; Perez-Victoria, J.M.; Sardo, A.; Ahmed-Belkacem, A.; Di Pietro, A. Purification of breast cancer resistance protein ABCG2 and role of arginine- 482. Cell. Mol. Life Sci., 2006, 63(16), 1912-1922.
64. Ozvegy, C.; Varadi, A.; Sarkadi, B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. J. Biol. Chem., 2002, 277(50), 47980-47990. (Pubitemid 35470743)
65. Szakacs, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov., 2006, 5 (3), 219-234. (Pubitemid 43336035)
66. Florin, A.; Boutonnat, J.; Boumendjel, A. Overcoming BCRP-mediated multidrug resistance. Drugs of the Future, 2008, 33(6), 533-542.
67. Ahmed-Belkacem, A.; Pozza, A.; Macalou, S.; Perez-Victoria, J. M.; Boumendjel, A.; Di Pietro, A. Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2). Anti-Cancer Drugs, 2006, 17, 239-244.
68. de Bruin, M.; Miyake, K.; Litman, T.; Robey, R.W.; Bates, S.E. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett., 1999, 146, 117-126. (Pubitemid 29492880)
69. Boumendjel, A.; Macalou, S.; Ahmed-Belkacem, A.; Blanc, M.; Di Pietro, A. Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2. Bioorg. Med. Chem., 2007, 15, 2892-2897. (Pubitemid 46402973)
70. Kühnle, M.; Egger, M.; Muller, C.; Mahringer, A.; Bernhardt, G.; Fricker, G.; Konig, B.; Buschauer, A. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J. Med. Chem., 2009, 52, 1190-1197.
71. Lee, J.S.; Scala, S.; Matsumoto, Y.; Dickstein, B.; Robey, R.W.; Zhan, Z.; Altenberg, G.; Bates, S.E. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J. Cell. Biochem. 1997, 65, 513-526. (Pubitemid 27240917)
72. Qadir, M.; O'Loughlin, K.L.; Fricke, S.M.; Williamson, N.A.; Greco, W.R.; Minderman, H.; Baer, M.R. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin. Cancer Res., 2005, 11, 2320-2326. (Pubitemid 40490193)
73. Gupta, A.; Dai, Y.; Vethanayagam, R.R.; Hebert, M.F.; Thummel, K.E.; Unadkat, J.D.; Ross, D.D.; Mao, Q. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother. Pharmacol., 2006, 58, 374-383. (Pubitemid 43800742)
74. Wang, X.; Baba, M. The role of breast cancer resistance protein (BCRP/ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Antivir. Chem. Chemother., 2005, 16, 213-216. (Pubitemid 41139707)
75. Weiss, J.; Rose, J.; Storch, C.H.; Ketabi-Kiyanvash, N., Sauer, A.; Haefeli, W.E.; Efferth, T. Modulation of human BCRP (ABCG2) activity by anti- HIV drugs. J. Antimicrob. Chemother., 2007, 59, 238-245. (Pubitemid 47072063)
76. Houghton, P.J.; Germain, G.S.; Harwood, F.C.; Schuetz, J.D.; Stewart, C.F.; Buchdunger, E.; Traxler, P. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res., 2004, 64, 2333-2337. (Pubitemid 38523883)
77. Burger, H.; van Tol, H.; Boersma, A.W.; Brok, M.; Wiemer, E.A.; Stoter, G.; Nooter, K. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood, 2004, 104, 2940-2942. (Pubitemid 39434984)
78. Ozvegy-Laczka, C.; Hegedus, T.; Varady, G.; Ujhelly, O.; Schuetz, J.D.; Varadi, A.; Keri, G.; Orfi, L.; Nemet, K.; Sarkadi, B. High-affinity interact tion of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol., 2004, 65, 1485-1495. (Pubitemid 38668306)
79. Hikaru, S.; Ran, A.; Hiroyuki, H.; Toshihisa, I. Emerging new technology: QSAR analysis and MO calculation to characterize interactions of protein kinase inhibitors with the human ABC transporter, ABCG2 ( BCRP ). Drug Metab. Pharmacok., 2010, 25, 72-83.
80. Brooks, T.A.; Minderman, H.; O'Loughlin, K.L.; Pera, P.; Ojima, I.; Baer, M.R.; Bernacki, R.J. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol. Cancer Ther., 2003, 2, 1195-1205.
81. Limtrakul, P.; Chearwae, W.; Shukla, S.; Phisalphong, C.; Ambudkar, S.V. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol. Cell. Biochem., 2007, 296, 85-95.
82. Chearwae, W.; Shukla, S., Limtrakul, P.; Ambudkar, S.V. Modulation of the function of multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol. Cancer Ther., 2006, 5, 1995-2006. (Pubitemid 44336571)
83. Shukla, S.; Zaher, H.; Hartz, A.; Bauer, B.; Ware, J.A.; Ambudkar, S.V. Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistancelinked ABC drug transporter in mice. Pharm. Res., 2009, 26, 480-487.
84. Jin, J.; Shahi, S.; Kang, H.K., van Veen, H.W.; Fan, T.P. Metabolites of ginsenosides as novel BCRP inhibitors. Biochem. Biophys. Res. Commun., 2006, 345, 1308-1314. (Pubitemid 43817877)
85. Holland, M.L.; Lau, D. T.; Allen, J.D.; Arnold, J.C. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br. J. Pharmacol., 2007,152, 815-824. (Pubitemid 350034987)
86. Rabindran, S.K.; He, H.; Singh, M.; Brown, E.; Collins, K.I.; Annable, T.; Greenberger, L.M. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res., 1998, 58, 5850-5858. (Pubitemid 29006428)
87. van Loevezijn, A.; Allen, J.D.; Schinkel, A.H.; Koomen, G.J. Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. Bioorg. Med. Chem. Lett., 2001, 11, 29-32. (Pubitemid 32006117)
88. Allen, J.D.; van Loevezijn, A.; Lakhai, J.M.; van der Valk, M.; van Tellingen, O.; Reid, G.; Schellens, J.H.M.; Koomen, G.J.; Schinkel, A.H. Potent and Specific Inhibition of the Breast Cancer Resistance Protein Multidrug Transporter in vitro and in Mouse Intestine by a Novel Analogue of Fumitremorgin C. Mol. Cancer Ther., 2002, 1, 417-425.
89. Woehlecke, H.; Osada, H.; Herrmann, A.; Lage, H. Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A. Int. J. Cancer, 2003, 107, 721-728. (Pubitemid 37339725)
90. Walsh, T.J.; Standiford, H.C.; Reboli, A.C., John, J.F.; Mulligan, M.E.; Ribner, B.S.; Montgomerie, J.Z.; Goetz, M.B.; Mayhall, C.G.; Rimland, D.; Stevens, D.A., Hansen, S.L.; Gerard, G.C.; Ragual, R. J. Randomized Double- Blinded Trial of Rifampin with Either Novobiocin or Trimethoprim- Sulfamethoxazole against Methicillin-Resistant Staphylococcus aureus Colonization: Prevention of Antimicrobial Resistance and Effect of Host Factors on Outcome. Antimicrob. Agents Chemother., 1993, 37(6), 1334-1342. (Pubitemid 23166736)
91. Yang, C.H.; Chen, Y.C.; Kuo, M.L. Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone. Anticancer Res., 2003, 23(3B), 2519-2523.
92. Shiozawa, K.; Oka, M.; Soda, H.; Yoshikawa, M.; Ikegami, Y.; Tsurutani, J.; Nakatomi, K.; Nakamura, Y.; Doi, S.; Kitazaki, T.; Mizuta, Y.; Murase, K.; Yoshida, H.; Ross, D.D.; Kohno, S. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int. J. Cancer., 2004, 108(1), 146-151. (Pubitemid 37444457)
93. Su, Y.; Sinko, P.J. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPTK5 cells: evidence for multifactorial multidrug resistance. Eur. J. Pharm. Sci., 2006, 29(2), 102-110. (Pubitemid 44332882)
94. Pick, A.; Müller, H.; Wiese, M. Novel lead for potent inhibitors of breast cancer resistance protein (BCRP). Bioorg. Med. Chem. Lett., 2010, 20, 180-183.
95. Pick, A.; Klinkhammer, W.; Wiese, M. Specific inhibitors of the Breast Cancer Resistance Protein (BCRP). ChemMedChem., 2010, 5, 1498-1505.
96. Cooray, H.C.; Janvilisri, T.; van Veen, H.W.; Hladky, S.B.; Barrand, M.A. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem. Biophys. Res. Commun., 2004, 317, 269-275. (Pubitemid 38401995)
97. Zhang, S.; Yang, X.; Morris, M.E. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol., 2004, 65, 1208-1216. (Pubitemid 38543491)
98. Zhang, S.; Yang, X.; Morris, M.E. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm. Res., 2004, 21, 1263-1273. (Pubitemid 38954213)
99. Ahmed-Belkacem, A.; Pozza, A.; Munoz-Martinez, F.; Bates, S.E.; Castanys, S.; Gamarro, F.; Di Pietro, A.; Perez-Victoria, J.M. Flavonoid structureactivity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res., 2005, 65, 4852-4860. (Pubitemid 40740824)
100. Katayama, K.; Masuyama, K.; Yoshioka, S.; Hasegawa, H.; Mitsuhashi, J.; Sugimoto, Y. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship. Cancer Chemother. Pharmacol., 2007, 60, 789-797. (Pubitemid 47389385)
101. An, G.; Morris, M. E. Effects of single and multiple flavonoids on BCRPmediated accumulation, cytotoxicity and transport of mitoxantrone in vitro. Pharm. Res., 2010, 27, 1296-1308.
102. Liu, X.L.; Tee, H.W.; Go, M.L. Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein. Bioorg. Med. Chem., 2008, 16(1), 171-180.
103. Han, Y.; Riwanto, M.; Go, M.L.; Rachel Ee, P.L. Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues. Eur. J. Pharm. Sci., 2008, 35(1-2), 30-41.
104. Macalou, S.; Ahmed-Belkacem, A.; Borelli, F.; Capasso, R.; Fattorusso, E.; Taglialatela-Scafati, O; Di Pietro, A. Non-prenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors. J. Med. Chem., 2007, 50, 1933-1938. (Pubitemid 46626602)
105. Boumendjel, A.; Nicolle, E.; Moraux, T.; Gerby, B. ; Blanc, M.; Ronot, X.; Boutonnat, J. Piperazinobenzopyranones and Phenalkylaminobenzopyranones: Potent Inhibitors of Breast Cancer Resistance Protein (ABCG2). J. Med. Chem., 2005, 48, 7275-7281. (Pubitemid 41743640)
106. Ecker, G.F.; Stockner, T.; Chiba P. Computational models for prediction of interactions with ABC-transporters. Drug. Discov. Today, 2008, 13(7-8), 311-317.
107. Gandhi, Y.A.; Morris, M.E. Structure-Activity Relationships and Quantitative Structure-Activity Relationships for breast cancer resistance protein (ABCG2), AAPS J., 2009, 11(3), 541-552.
108. Zhang, S.; Yang, X.; Coburn, R.A.; Morris, M.E. Structure activity relationships and quantitative structure activity relationships for the flavonoidmediated inhibition of breast cancer resistance protein, Biochem Pharmacol., 2005, 70, 627-639. (Pubitemid 40978553)
109. Nicolle, E.; Boccard, J.; Guilet, D.; Dijoux, M.-G.; Zelefac, F.; Macalou, S., Schmidt, J. ; Di Pietro, A.; Boumendjel, A. New inhibitors and QSAR studies by a 3D linear solvation-energy approach, Eur. J. Pharm. Sci., 2009, 38, 39-46.
110. Cruciani, G.; Crivori, P.; Carrupt, P.A.; Testa, B. Molecular fields in quantitative structure permeation relationships: the VolSurf approach. J. Mol. Struct. (Theochem), 2000, 503, 17-30.
111. Boccard, J.; Bajot, F.; Di Pietro, A.; Rudaz, S.; Boumendjel, A.; Nicolle, E., Carrupt, P.-A., Solvatochromic analysis of molecular interaction forces between flavonoid derivatives and P-glycoprotein, Eur. J. Pharm. Sci., 2009, 36, 254-264.
112. Pick, A.; Müller, H.; Wiese, M. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). Bioorg. Med. Chem., 2008, 16, 8224-8236.
113. Matsson, P.; Englund, G.; Ahlin, G.; Bergström, C.A.S.; Norinder, U.; Artursson, P. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2), J. Pharmacol. Exp. Ther., 2007, 323, 19-30. (Pubitemid 47443263)
114. Halgreen, T.A.; Damm, W. Polarizable force fields. Curr. Opin. Struct. Biol., 2001, 11, 236-242. (Pubitemid 32289428)
115. Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res., 1993, 53, 4595-4602. (Pubitemid 23304385)
116. Mistry, P.; Stewart, A.J.; Dangerfield, W., Okiji, S.; Liddle, C.; Bootle, D; Plumb, J.A.; Templeton, D.; Charlton, P. In vitro and in vivo reversal of Pglycoprotein- mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res., 2001, 61(2), 749-758. (Pubitemid 32128642)
117. Tamai, I.; Safa, A.R. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J. Biol. Chem., 1991, 266(25), 16796-16800. (Pubitemid 21907869)
118. Shukla, S.; Robey, R.W.; Bates, S.E.; Ambudkar, S.V. The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistancelinked ABC drug transporter, ABCG2. Biochemistry, 2006, 45(29), 8940-8951. (Pubitemid 44100690)
119. Gutmann, H.; Hruz, P.; Zimmermann, C.; Beglinger, C.; Drewe, J. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem Pharmacol., 2005, 70(5),695-699. (Pubitemid 41058704)
120. Maliepaard, M.; Scheffer, G.L.; Faneyte, I.F.; van Gastelen, M.A.; Pijnenborg, A.C.; Schinkel, A.H.; van De Vijver, M.J.; Scheper, R.J.; Schellens, J.H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res., 2001, 61(8), 3458-3464. (Pubitemid 32695041)
121. Vlaming, M.L.; Lagas, J.S.; Schinkel, A.H. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv. Drug Deliv. Rev., 2009, 61(1), 14-25.
122. Jonker, J.W.; Buitelaar, M.; Wagenaar, E.; Van Der Valk, M.A.; Scheffer, G.L.; Scheper, R.J.; Plosch, T.; Kuipers, F.; Elferink, R.P.; Rosing, H.; Beijnen, J.H.; Schinkel, A.H. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA., 2002, 99(24), 15649-15654. (Pubitemid 35403986)
123. Kuppens, I.E.; Witteveen, E.O.; Jewell, R.C.; Radema, S.A.; Paul, E.M.; Mangum, S.G.; Beijnen, J.H.; Voest, E.E.; Schellens, J.H. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res., 2007, 13(11), 3276-3285. (Pubitemid 46944913)
124. Dai, H.; Marbach, P.; Lemaire, M.; Hayes, M.; Elmquist, W.F. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J. Pharmacol. Exp. Ther., 2003, 304(3), 1085-1092. (Pubitemid 36254421)
125. Breedveld, P.; Pluim, D.; Cipriani, G.; Wielinga, P.; van Tellingen, O.; Schinkel, A.H.; Schellens, J.H. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res., 2005, 65(7), 2577-2582. (Pubitemid 40490054)
126. Chen, Y.; Agarwal, S.; Shaik, N.M.; Chen, C.; Yang, Z.; Elmquist, W.F. Pglycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J. Pharmacol. Exp. Ther., 2009, 330(3), 956-963.
127. Elmeliegy, M.A.; Carcaboso, A.M.; Tagen, M.; Bai, F.; Stewart, C.F. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin. Cancer Res., 2011, 17(1), 89-99.
128. Agarwal, S.; Sane, R.; Gallardo, J.L.; Ohlfest, J.R.; Elmquist, W.F. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J. Pharmacol. Exp. Ther., 2010, 334(1), 147-155.
129. Alvarez, A.I.; Real, R.; Pérez, M.; Mendoza, G.; Prieto, J.G.; Merino, G. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J. Pharm. Sci., 2010, 99(2), 598-617
130. Chearwae, W.; Anuchapreeda, S.; Nandigama, K.; Ambudkar, S.V.; Limtrakul, P. Biochemical mechanism of modulation of human Pglycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem. Pharmacol., 2004, 68(10), 2043-2052. (Pubitemid 39346194)
131. Merino, G.; Perez, M.; Real, R.; Egido, E.; Prieto, J.G.; Alvarez, A.I. In vivo inhibition of BCRP/ABCG2 mediated transport of nitrofurantoin by the isoflavones genistein and daidzein: a comparative study in Bcrp1 (-/-) mice. Pharm. Res., 2010, 27(10), 2098-2105.
132. Nassar, I.; Pasupati, T.; Judson, J.P.; Segarra, I. Reduced exposure of imatinib after coadministration with acetaminophen in mice. Indian J. Pharmacol., 2009, 41, 167-172.
133. Lee, J.K.; Abe, K.; Bridges, A.S.; Patel, N.J.; Raub, T.J.; Pollack, G.M.; Brouwer, K.L. Sex-dependent disposition of acetaminophen sulfate and glucuronide in the in situ perfused mouse liver. Drug Metab. Dispos., 2009, 37(9), 1916-1921.
134. Liukas, A.; Kuusniemi, K.; Aantaa, R.; Virolainen, P.; Niemi, M.; Neuvonen, P.J.; Olkkola, K.T. Pharmacokinetics of intravenous paracetamol in elderly patients. Clin. Pharmacokinet., 2011, 50(2), 121-129.
135. Hosten, B.; Abbara, C.; Cibert, M.; Petit, B.; Farinotti, R.; Gonin, P.; Bonhomme-Faivre, L. Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice. Anticancer Drugs., 2010, 21(2), 193-201.
136. Agarwal, S.; Sane, R.; Ohlfest, J.R.; Elmquist, W.F. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J. Pharmacol. Exp. Ther., 2011, 336(1), 223-233.
137. Stewart, C.F.; Leggas, M.; Schuetz, J.D.; Panetta, J.C.; Cheshire, P.J.; Peterson, J.; Daw, N.; Jenkins, J.J. 3rd, Gilbertson, R.; Germain, G.S.; Harwood, F.C.; Houghton, P.J. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res., 2004, 64, 7491-7499. (Pubitemid 39372093)
138. Arnaud, O.; Boumendjel, A.; Gèze, A.; Honorat, M.; Matera, E.L.; Guitton, J.; Stein, W.D.; Bates, S.E.; Falson, P.; Dumontet, C.; Di Pietro, A.; Payen, L. The acridone derivative MBLI-87 sensitizes breast cancer resistance protein- expressing xenografts to irinotecan. Eur. J. Cancer., 2011, in press.
139. Peng, H.; Dong, Z.; Qi, J.; Yang, Y.; Liu, Y.; Li, Z.; Xu, J.; Zhang, J.T. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy. PLoS One., 2009, 4(5):e5676.
140. Peng, H.; Qi, J.; Dong, Z.; Zhang, J.T. Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells. PLoS One., 2010, 5(12):e15276.
141. Garimella, T.S.; Ross, D.D.; Eiseman, J.L.; Mondick, J.T.; Joseph, E.. Nakanishi, T.; Bates, S.E.; Bauer, K.S. Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors. Cancer Chemother. Pharmacol., 2005, 55(2), 101-109. (Pubitemid 40110052)
142. Zhang, Y.; Bressler, J.P.; Neal, J.; Lal, B.; Bhang, H.E.; Laterra, J.; Pomper, M.G. ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. Cancer Res., 2007, 67(19), 9389-9397. (Pubitemid 47535929)
143. Yanase, K.; Tsukahara, S.; Asada, S.; Ishikawa, E.; Imai, Y.; Sugimoto, Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol. Cancer Ther., 2004, 3(9), 1119-1125. (Pubitemid 39295009)
144. Lemos, C.; Jansen, G.; Peters, G.J. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br. J. Cancer, 2008, 98, 857-862. (Pubitemid 351341599)
145. Leggas, M.; Panetta, J.C.; Zhuang, Y.; Schuetz, J.D.; Johnston, B.; Bai, F.; Sorrentino, B.; Zhou, S.; Houghton, P.J.; Stewart, C.F. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res., 2006, 66, 4802-4807.
146. McKillop, D.; Partridge, E.A.; Hutchison, M.; Rhead, S.A.; Parry, A.C.; Bardsley, J.; Woodman, H.M.; Swaisland, H.C. Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog. Xenobiotica, 2004, 34, 901-915. (Pubitemid 39648169)
147. Kawamura, K.; Yamasaki, T.; Yui, J.; Hatori, A.; Konno, F.; Kumata, K.; Irie, T.; Fukumura, T.; Suzuki, K.; Kanno, I.; Zhang, M.R. In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using[(11)C]gefitinib. Nucl. Med. Biol., 2009, 36, 239-246.
148. Sai, K.; Saito, Y.; Maekawa, K.; Kim, S.R.; Kaniwa, N.; Nishimaki-Mogami, T.; Sawada, J.; Shirao, K.; Hamaguchi, T.; Yamamoto, N.; Kunitoh, H.; Ohe, Y.; Yamada, Y.; Tamura, T.; Yoshida, T.; Matsumura, Y.; Ohtsu, A.; Saijo, N.; Minami, H. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother. Pharmacol., 2011, 66, 95-105.
149. Pérez-Victoria, J.M.; Cortés-Selva, F.; Parodi-Talice, A.; Pérez-Victoria, F.J.; Muñoz-Martínez, F.; Maitrejean, M.; Costi, M.P.; Jiménez, I.A.; Barron, D.; Di Pietro, A.; Castanys, S.; and Gamarro, F.A. Combination of inhibitor subdoses targeting different domains of LtrMDR1 efficiently overcomes Leishmania resistance to miltefosine. Antimicrob. Agents Chemother., 2006, 50, 3102-3110. (Pubitemid 44396418)
150. Aller, S.G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P.M.; Trinh, Y.T.; Zhang, Q.; Urbatsch, I.L.; Chang, G. Structure of Pglycoprotein reveals a molecular basis for poly-specific drug binding. Science, 2009, 323(5922), 1718-1722.
151. Dawson, R.J.; Locher, K.P. Structure of a bacterial multidrug ABC transporter. Nature, 2006, 443(7108),180-185. (Pubitemid 44387602)
152. Kerr, I.D.; Jones, P.M.; George, A.M. Multidrug efflux pumps: the structures of prokaryotic ATP-binding cassette transporter efflux pumps and implications for our understanding of eukaryotic P-glycoproteins and homologues. FEBS J., 2010, 277(3), 550-563.
153. Wang, H.; Lee, E.W.; Cai, X.; Ni, Z.; Zhou, L.; Mao, Q. Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence. Biochemistry, 2008, 47(52),13778-13787.